Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS clinical trials group protocol 315

Michael M. Lederman, Elizabeth Connick, Alan Landay, Daniel R. Kuritzkes, John Spritzler, Marty St Clair, Brian L. Kotzin, Lawrence Fox, Margo Heath Chiozzi, John M. Leonard, Franck Rousseau, Michael Wade, Joana D.Arc Roe, Ana Martinez, Harold Kessler

Research output: Contribution to journalArticlepeer-review

370 Scopus citations

Abstract

Human immunodeficiency virus (HIV)-1 infection is associated with progressive cell-mediated immune deficiency and abnormal immune activation. Although highly active antiretroviral therapy regimens can increase circulating CD4 T lymphocyte counts and decrease the risk of opportunistic complications, the effects of these treatments on immune reconstitution are not well understood. In 44 persons with moderately advanced HIV-1 infection, after 12 weeks of treatment with zidovudine, lamivudine, and ritonavir, plasma HIV-1 RNA fell a median of 2.3 logs (P < .0001). Circulating numbers of naive and memory CD4 T lymphocytes (P < .001), naive CD8 T lymphocytes (P < .004), and B lymphocytes (P < .001) increased. Improved lymphocyte proliferation to certain antigens and a tendency to improvement in delayed- type hypersensitivity also were seen. Dysregulated immune activation was partially corrected by this regimen; however, the perturbed expression of T cell receptor V regions in the CD4 and CD8 T lymphocyte population was not significantly affected. Ongoing studies will ascertain if longer durations of virus suppression will permit more complete immune restoration.

Original languageEnglish (US)
Pages (from-to)70-79
Number of pages10
JournalJournal of Infectious Diseases
Volume178
Issue number1
DOIs
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS clinical trials group protocol 315'. Together they form a unique fingerprint.

Cite this